Holen Sie sich die Stockscreener-App
52.15
0.38%
0.20
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BMY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$51.95
Offen:
$51.99
24-Stunden-Volumen:
15.66M
Relative Volume:
0.98
Marktkapitalisierung:
$106.16B
Einnahmen:
$48.03B
Nettoeinkommen (Verlust:
$6.05B
KGV:
17.61
EPS:
2.9615
Netto-Cashflow:
$15.30B
1W Leistung:
+6.00%
1M Leistung:
+12.22%
6M Leistung:
+9.01%
1J Leistung:
-11.37%
1-Tages-Spanne:
$51.69
$52.51
1-Wochen-Bereich:
$48.22
$52.51
52-Wochen-Spanne:
$42.52
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
Firmenname
Bristol Myers Squibb Co
Sektor
Telefon
(609) 252-4621
Adresse
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Vergleichen Sie BMY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
52.15 | 105.76B | 48.03B | 6.05B | 15.30B | 2.9615 |
|
LLY
Lilly Eli Co
|
1,010.31 | 907.99B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
201.93 | 487.83B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
226.08 | 404.22B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
132.16 | 254.11B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
99.72 | 250.41B | 63.90B | 19.05B | 13.05B | 7.5596 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Perform |
| 2025-08-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2025-04-22 | Eingeleitet | Piper Sandler | Overweight |
| 2024-12-16 | Hochstufung | Jefferies | Hold → Buy |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-13 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-07-29 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-03-11 | Herabstufung | Societe Generale | Buy → Hold |
| 2024-02-06 | Herabstufung | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-11-15 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-02 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-10-27 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-10 | Eingeleitet | SVB Securities | Market Perform |
| 2023-06-28 | Eingeleitet | Daiwa Securities | Outperform |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-01-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-11-18 | Eingeleitet | Credit Suisse | Neutral |
| 2022-10-10 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-09-14 | Herabstufung | Berenberg | Buy → Hold |
| 2022-06-03 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Underweight |
| 2021-12-17 | Eingeleitet | Goldman | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-01 | Herabstufung | Argus | Buy → Hold |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | Hochstufung | Truist | Hold → Buy |
| 2020-11-16 | Hochstufung | Societe Generale | Hold → Buy |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-11-06 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2020-10-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2020-07-28 | Eingeleitet | Raymond James | Outperform |
| 2020-04-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-01-06 | Fortgesetzt | Citigroup | Buy |
| 2019-12-13 | Hochstufung | Argus | Hold → Buy |
| 2019-11-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-08-14 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-05-20 | Herabstufung | Argus | Buy → Hold |
| 2019-05-03 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-05-03 | Fortgesetzt | JP Morgan | Overweight |
| 2019-01-15 | Hochstufung | Societe Generale | Sell → Buy |
| 2018-10-22 | Herabstufung | Citigroup | Buy → Neutral |
Alle ansehen
Bristol Myers Squibb Co Aktie (BMY) Neueste Nachrichten
Cresset Asset Management LLC Decreases Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Shares Sold by Epoch Investment Partners Inc. - MarketBeat
Jim Cramer on Bristol-Myers’ Recent Stock Gain: “Unbelievable” - Insider Monkey
Do These 3 Healthcare Stocks Need a Checkup? - The Motley Fool
What's Going On With Bristol-Myers Squibb Stock Friday?Bristol-Myers Squibb (NYSE:BMY) - Benzinga
Bristol Myers Squibb CEO Chris Boerner says company culture was the missing piece of his ‘patent cliff’ plan - Fortune
First Trust Advisors LP Has $212.59 Million Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL) – Company AnnouncementFT.com - Financial Times
DEERFIELD MANAGEMENT COMPANY, L.P.'s Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Rx Rundown: Bristol Myers Squibb, Retro Bio, Ionis Pharmaceuticals and more - Medical Marketing and Media
How risky is Bristol Myers Squibb Company stock compared to peers2025 Market WrapUp & Free Risk Controlled Daily Trade Plans - Newser
Bristol Myers Pushes Data Readout For Key Alzheimer's Psychosis Study After Irregularities - Sahm
BMY Gains on News of Continuation of Alzheimer's Disease Study - Finviz
Florida key to BMS slip in ADP? Acadia sails ahead - BioWorld MedTech
Scotiabank raises Bristol-Myers Squibb stock price target to $53 on pipeline - Investing.com Nigeria
Invesco Ltd. Raises Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
CW Advisors LLC Increases Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Why Bristol Myers Squibb Company Celegne Contingent stock is a must watch tickerGlobal Markets & Stock Timing and Entry Methods - Newser
Bristol-Myers Squibb (BMY) Stock Surges on Cobenfy Trial Twist and AI Milestone: Full Outlook as of December 3, 2025 - ts2.tech
What's Going On With Bristol-Myers Squibb Shares Wednesday?Bristol-Myers Squibb (NYSE:BMY) - Benzinga
Shares of Bristol Myers Squibb rise despite delay in clinical trial of promising drug - MarketWatch
Bristol-Myers Squibb stock holds Buy rating at Truist despite trial delay - Investing.com
A delayed clinical trial actually boosted Bristol Myers Squibb’s stock. Here’s why. - MarketWatch
After finding ‘irregularities,’ Bristol Myers to extend key trial of Cobenfy in Alzheimer’s psychosis - BioPharma Dive
Bristol Myers Squibb (BMY) Delays Alzheimer's Drug Trial Results - GuruFocus
Bristol Myers (BMY) Extends ADEPT-2 Study Timeline for Key Alzhe - GuruFocus
Bristol Myers (BMY) Advances in Alzheimer's Study Facing Trial C - GuruFocus
Bristol Myers (BMY) Bolsters ADEPT-2 Alzheimer's Study with More Participants - GuruFocus
Terray Therapeutics Achieves AI-Enabled Drug Discovery Milestone in Collaboration with Bristol Myers Squibb - Yahoo Finance
Bristol Myers Stock Jumps As Wall Street Backs Added Enrollment In Alzheimer’s Trial — Retail Calls It ‘Worth A Play’ - Stocktwits
Drug Trial Wins Give Health Care Stocks A Shot - Finimize
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Bristol Myers rises as Alzheimer's trial to enroll more patients - TradingView
M&T Bank Corp Sells 23,588 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers (BMY) Expands ADEPT-2 Study to Address Irregularit - GuruFocus
River Road Asset Management LLC Sells 67,650 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
BMS to enroll more patients in Alzheimer’s psychosis drug trial - Investing.com
Bristol Myers Squibb stock rises after continuing Phase 3 Alzheimer’s study - Investing.com Canada
Loomis Sayles & Co. L P Boosts Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Independent Franchise Partners LLP Increases Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Stock Rises on Alzheimer’s Drug Study Update - The Wall Street Journal
Cantor Fitzgerald Maintains Price Target on Bristol-Myers (BMY) Amid Milvexian Updates - Insider Monkey
BMS Executive: AI to Reshape Pharmaceutical, Biotech Industries - 조선일보
Bristol-Myers Squibb (BMY): Assessing Value After a Recent Short-Term Share Price Rebound - simplywall.st
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors - MarketWatch
Judge Trims but Revives Core Claims in Bristol-Myers $6.7B Suit - USA Herald
BMY: Goldman Sachs Raises Bristol-Myers Squibb Price Target to $57 | BMY Stock News - GuruFocus
Bristol-Myers to Face $6.7 Billion Celgene Deal Payout Suit (1) - Bloomberg Law News
Wealthedge Investment Advisors LLC Buys New Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Shelton Capital Management Cuts Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Claret Asset Management Corp Grows Position in Bristol Myers Squibb Company $BMY - MarketBeat
Finanzdaten der Bristol Myers Squibb Co-Aktie (BMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.21%
0.98%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):